Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ancient eggshells shed new light on crocodiles that hunted prey from trees - 24 Jeep Models: Dominating Execution and Flexibility for Each Experience
- 3Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- 4Vote in favor of your Favored kind of footwear
- 5Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- Choosing Moving Styles for Your Restroom Redesign
- Collins Foods to offload 20 Taco Bell outlets in Australia
- NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- EU foreign ministers commemorate Russian massacre in Bucha
- Get away from the Tedious Drudgery: Go into Business Today!
